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Abstract:  -aminobutyric acid (GABA) plays important roles in the central nervous system, acting as a neurotransmitter on both 
ionotropic ligand-gated Cl
--channels, and metabotropic G-protein coupled receptors (GPCRs). These two types of receptors called 
GABAA (and C) and GABAB are the targets of major therapeutic drugs such as the anxiolytic benzodiazepines, and antispastic drug ba-
clofen (lioresal®), respectively. Although the multiplicity of GABAA receptors offer a number of possibilities to discover new and more 
selective drugs, the molecular characterization of the GABAB receptor revealed a unique, though complex, heterodimeric GPCR. High 
throughput screening strategies carried out in pharmaceutical industries, helped identifying new compounds positively modulating the ac-
tivity of the GABAB receptor. These molecules, almost devoid of apparent activity when applied alone, greatly enhance both the potency 
and efficacy of GABAB agonists. As such, in contrast to baclofen that constantly activates the receptor everywhere in the brain, these 
positive allosteric modulators induce a large increase in GABAB-mediated responses only WHERE and WHEN physiologically needed. 
Such compounds are then well adapted to help GABA to activate its GABAB receptors, like benzodiazepines favor GABAA receptor acti-
vation. In this review, the way of action of these molecules will be presented in light of our actual knowledge of the activation mecha-
nism of the GABAB receptor. We will then show that, as expected, these molecules have more pronounced in vivo responses and less side 
effects than pure agonists, offering new potential therapeutic applications for this new class of GABAB ligands. 
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INTRODUCTION 
  As one of the major neurotransmitters in the brain, -amino-
butyric acid (GABA) plays critical roles in brain development and 
physiology. By activating GABAA receptors, which are Cl
--gated 
channels, this neurotransmitter prevents neuronal depolarization, 
and as such controls the transmission of excitatory signals. In young 
animals, these GABAA receptors generate instead excitatory re-
sponses, and replace the glutamatergic system not yet fully estab-
lished. Controlling GABAA receptor activity soon appeared as an 
interesting way for the treatment of brain dysfunction. This led to 
the discovery of benzodiazepines that allosterically enhance 
GABAA receptor activation by acting at a site distinct from the 
GABA binding site. These positive modulators act by increasing 
GABA affinity and potency, and by facilitating Cl
--channel open-
ing, and are widely used for the treatment of insomnia, anxiety and 
epilepsies. 
  GABA also acts on G protein-coupled GABAB receptors [6]. 
These receptors limit neurotransmitter release at many synapses, 
including most GABAergic and glutamatergic ones, by inhibiting at 
least Ca
2+-channel opening. They are also located in post-synaptic 
elements where they activate G protein-regulated inward-rectifying 
K
+-channels (GIRK channels) [42]. These receptors were pharma-
cologically identified in the early 80's, being selectively activated 
by baclofen ( p-chlorophenyl-GABA) [31], a molecule that is used 
for the treatment of spasticity in multiple sclerosis patients due to 
its muscle-relaxant properties [9]. The GABAB receptors are also 
responsible for most effects of the drug of abuse gamma-
hydroxybutyrate (GHB) that acts as a GABAB partial agonist at 
high doses [34, 48]. GABAB agonists also demonstrated a number 
of beneficial effects both in animals and in humans [5]. Indeed, 
activation of GABAB receptors exerts analgesic/antinociceptive 
effects in animal models of chronic inflammation and neuropathy 
(see [5]), suppresses drug seeking behavior [15], and has some 
anxiolytic activity both in animal models and in human [17]. How-
ever, undesired side effects such as hypothermic and sedative ef-
fects, greatly limits the use of GABAB agonists in therapeutics [5]. 
Moreover, tolerance to baclofen chronic treatment is well estab-
lished [44]. In addition to agonists, GABAB antagonists were also  
*Address correspondence to this author at Institut de Génomique Fonction-
nelle, 141, rue de la cardonille, 34094, Montpellier cedex 5, France; Tel: 
+33 467 14 2988; Fax: +33 467 54 2432; E-mail: jppin@igf.cnrs.fr 
shown to have potential therapeutic effects, such as antidepressant 
activity [17], cognition improvement [22], and beneficial effects in 
rat models of absence epilepsy [53]. 
 GABAB receptors have therefore been used as a target in high 
throughput screening strategies with the aim at identifying new 
ligands acting at this receptor. As already well documented for the 
related metabotropic glutamate (mGlu) receptors [26, 28], this 
strategy leads to the discovery of allosteric modulators acting at the 
GABAB receptor [76, 77]. In contrast to mGluRs for which both 
positive and negative (non-competitive antagonists) were identified, 
only positive allosteric modulators (PAMs) have been described so 
far for the GABAB receptor. These compounds display no or very 
partial agonist activity, but enhance both the potency and efficacy 
of GABAB agonists. As such, these molecules appear as a better 
alternative to GABAB agonists, allowing the specific enhancement 
of GABAB receptor activity when and where needed, and as such, 
are less prone to tolerance in contrast to the pure agonists that con-
stantly activate the receptor in any region where it is expressed. 
  In the present chapter, we aimed at describing the mechanism 
of action of the identified allosteric modulators of the GABAB re-
ceptor. We will first describe our current knowledge of the func-
tioning of this complex receptor (for reviews see [2, 65]). We will 
then highlight the potential new therapeutic possibilities offered by 
these molecules, as based on the recent preclinical studies reported 
in the literature. 
STRUCTURE AND ACTIVATION MECHANISM OF THE 
GABAB RECEPTOR 
 The  GABAB receptor is part of the class C of GPCRs that also 
includes the mGlu, the Ca
2+-sensing, and the sweet and umami taste 
receptors among others [64]. These receptors are dimers, either 
homodimers linked by a disulphide bond (mGlu and Ca
2+-sensing 
receptors), or heterodimers made of two similar, but distinct 
subunits (the GABAB and taste receptors). Indeed, the GABAB
receptor was the first GPCR to be identified that requires two dis-
tinct subunits to function: the GABAB1 and GABAB2 subunits [33, 
36, 79] (Fig. 1). Although the GABAB1 subunit was soon shown to 
bind all known GABAB ligands (both agonists and antagonists), this 
protein did not form a functional GABAB receptor when expressed 
alone [35]. Only when GABAB1 was co-expressed with the ho-
mologous GABAB2 subunit was a functional GABAB receptor ob-
served, either in cell lines or in cultured neurons. The GABAB di-
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GABAB1 and GABAB2 mRNAs are co-localized in most brain re-
gions. Second, both proteins are found in the same neurons, even in 
the same subcellular compartments as observed at the electron mi-
croscopic level. Moreover, co-immunoprecipitation of GABAB1
with a GABAB2 antibody could be demonstrated from brain mem-
branes. Eventually, mice lacking either GABAB1 or GABAB2 share 
very similar phenotypes, and none of the known GABAB-mediated 
responses could be measured in either mice [66, 69]. Although 
unusual baclofen-mediated inhibition of GIRK channels could be 
observed in mice lacking GABAB2, it is still not known whether this 
represents a natural response, or is the consequence of the absence 
of the GABAB2 subunit. Taken together, these data demonstrate that 
the assembly between these two proteins is required to get a func-
tional GABAB receptor in native tissues. 
    When expressed alone, the GABAB1 subunit is mostly 
retained in the endoplasmic reticulum (ER), both in transfected cell 
lines and in neurons [16]. This is due to the presence of an intracel-
lular retention signal (RXR) located in its intracellular tail that con-
stitutes a binding site for the coat protein-I complex (COPI) [8, 10, 
54, 61]. COPI is known to target back to the ER proteins that 
reached the cis-Golgi, therefore preventing their trafficking through 
the Golgi and their targeting to the cell surface. COPI binding to the 
RXR motif of GABAB1 is prevented by GABAB2 thanks to a direct 
interaction between the intracellular tails of these two subunits 
through a coiled-coil interaction [8, 10, 54, 61]. Such a system is 
assumed to control the trafficking to the cell surface of correctly 
assembled GABAB heterodimers. 
 Each  GABAB receptor subunit is made of two main domains: a 
large extracellular domain structurally similar to bacterial periplas-
mic amino-acid binding proteins often called a Venus Flytrap do-
main (VFT) [24], linked to a 7 transmembrane domain (the hepta-
helical domain (HD)) typical of all GPCRs (Fig. 1). Besides these 
common features, most class C GPCRs, except the GABAB recep-
tor subunits, possess a cystein-rich domain that interconnects, both 
physically and functionally, the VFT and the HD in mGlu receptors 
[68]. A third domain composed of two short consensus repeats, also 
known as Sushi domains, is found at the N-terminus of the 
GABAB1a splice variant but in the GABAB1b variant, [30, 35]. 
These Sushi domains are responsible for the specific targeting of 
the GABAB1a receptor in nerve terminals of glutamatergic neurons 
[78]. 
  The VFT domain of class C GPCRs contains the binding site 
for agonists and competitive antagonists (the orthosteric ligands). In 
the case of the GABAB receptor, GABA and all other orthosteric 
ligands bind to the GABAB1 VFT only, notably by interacting with 
Ser246 and Glu465 (nomenclature based on the rat GABAB1a se-
quence) [24, 39, 52]. Indeed, mutational and evolution analyses of 
the GABAB2 VFT suggest that no natural ligand binds in this do-
main [39]. 
  Although GABA binds in the GABAB1 VFT, it is now well 
demonstrated that the GABAB2 HD is responsible for G-protein 
activation (Fig. 1). Indeed, a mutated receptor dimer with two 
GABAB2 HDs is functional, whereas a mutated receptor with two 
GABAB1 HDs does not [23]. Moreover, mutations in either the 
second or third intracellular loop of GABAB2 suppress G-protein 
activation whereas the equivalent mutations in GABAB1 do not [21, 
29, 67]. Finally, a recent study identified an Arg residue at the bot-
tom of TM3 conserved in most class C GPCRs that plays a critical 
role in G-protein activation [4]. This Arg may possibly play a role 
similar to that of the conserved D/ERY motif of class A GPCRs. Of 
interest, this Arg is found in the GABAB2, but not in the GABAB1,
further highlighting the pivotal role played by GABAB2 in G-
protein activation. 
  Howcan agonist binding in GABAB1 VFT activate the GABAB2
HD? Much information to answer that question came from the 
solved crystal structure of the mGlu1 VFT dimer with and without 
bound agonist or antagonist [43, 73]. These structures revealed that 
agonist binding in the VFT stabilizes a closed conformation that is 
also associated with a major change in the relative orientation of the 
two VFTs in the dimer (Fig. 1). This relative movement is expected 
to induce a relative movement of the HDs, a proposal that is consis-
tent with FRET studies [72]. Of interest, although both HDs in a 
mGlu homodimer are identical, this process leads to the active state 
of only one of them [32], likely because a single G-protein can 
interact at a time with such dimeric entities [19]. This model per-
fectly fits with all mutational analysis of GABAB receptor function-
ing. Indeed, the closure of the GABAB1 VFT has been shown to be 
responsible for GABAB receptor activation [40], and such a closure 
activates GABAB2 HD whether it is part of the associated subunit 
(like in the wild-type heterodimer) or linked to the GABAB1 VFT 
[23]. Moreover, point mutations introduced into either the GABAB1
VFT or the GABAB2 HD were found to increase constitutive activ-
ity of this receptor, consistent with these two domains playing a 
critical role in receptor activation [56]. 
  In summary, the GABAB receptor is a complex allosteric pro-
tein made or four main domains working "de concert" to allow 
GABA binding in the VFT of one subunit (GABAB1) to activate the 
HD of the associated subunit (GABAB2), likely through relative 
movement between these domains (Fig. 1). As we will see now, 
such a complex structure offers a number of possibilities to modu-
late GABAB receptor function. 
ALLOSTERIC MODULATORS OF THE GABAB RECEP-
TOR: PROPERTIES AND MECHANISM OF ACTION 
  Early studies following the molecular characterization of the 
GABAB receptor heterodimer indicated that Ca
2+ ions act as en-
hancers of this receptor [80]. Indeed, few hundred micromolar of 
Ca
2+ increased the potency of GABA in stimulating GTPS binding 
or G-protein activation measured in second messenger assays [25]. 
This effect is observed both with the recombinant and the native 
receptor [25], even in post-morten human tissues [58], and results 
from a direct increase in GABA affinity. Of interest, this effect of 
Fig. (1). Expected structure of the heterodimeric GABAB receptor in its 
inactive (left) and active (right) states. This receptor is made of two ho-
mologous subunits, GABAB1 (in the front, in black) and GABAB2 (in the 
back, in light grey). Each subunit is made of two main domains, the ex-
tracellular Venus Flytrap domain (VFT) and the heptahelical domain (HD). 
GABA and other orthosteric GABAB ligands are known to bind in the 
GABAB1 VFT. No known ligand bind at the equivalent site in GABAB2.
Only the GABAB2 HD appears to be responsible for G-protein coupling. 
These images were made using the coordinates of the dimer of mGlu1 VFTs 
in the inactive empty state (left) and those of the active Glu occupied state 
(right) [43], in association with a dimer of HD generated based on the pro-
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Ca
2+ was not observed with baclofen, suggesting that the chloro-
phenyl group of baclofen prevents the action of Ca
2+ ions, pointing 
to the possibility that Ca
2+ directly binds within the GABA binding 
site in the GABAB1 VFT. This was further validated using site di-
rected and 3D modeling studies [25]. According to the expected 
physiological Ca
2+ concentration range, the GABAB receptor is 
expected to be always potentiated under physiological condition. 
Only under pathological conditions, when the extracellular Ca
2+
concentration reaches values as low as few micromolar, can this 
effect disappear. Whatever, these data revealed that it is possible to 
positively modulate GABAB receptor function with small mole-
cules. 
  Few years before this observation, a number of allosteric modu-
lators of the other class C GPCRs, and especially mGlu receptors, 
were identified, including both negative and positive allosteric 
modulators [26, 28] (see this issue). The negative modulators first 
identified for mGlu1 and mGlu5, were found to inhibit in a non-
competitive manner the activity of the receptors, and to display in 
most cases inverse agonist activity [12, 62]. In contrast, PAMs were 
found to have no, or weak agonist activity when applied alone, but 
to greatly enhance both the potency and the efficacy of agonists 
[41, 57]. Both types of modulators were found to bind in a cavity 
within the HD, contacting residues of TM3, TM5 TM6 and TM7, 
therefore at a site clearly distinct from the glutamate binding site 
located in the VFT. Residues that constitute this binding site differ 
between receptor subtypes, such that most modulators identified so 
far, either positive or negative, were found to be highly subtype 
selective, in contrast to the orthosteric ligands that usually do not 
discriminate between mGlu receptors from the same group [26, 28]. 
  Taken together, these data indicated that compounds interacting 
in the HD of class C GPCRs could allosterically modulate their 
activity, and these compounds had three main advantages: 1) origi-
nal chemical structures, different from that of the orthosteric 
ligands, usually poly-cyclic with a good bioavailability, more prone 
to chemical modifications, and in agreement with the Lipinski's 
rules for drug-likelyness; 2) much higher selectivity among related 
sequences; and 3) a good respect of the biological activity of the 
receptors, especially for the PAMs that facilitate agonist action, and 
therefore enhance receptor activation when and where needed 
physiologically. 
  These observations lead a number of pharmaceutical companies 
to search for new GABAB modulators using high throughput func-
tional assays. So far, only 2 PAMs have been reported in the litera-
ture (2,6-Di-tert.-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol 
(CGP7930) and N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyri-
midine-4,6-diamine (GS39783) and some of their derivatives) [76, 
77] (Fig. 2), and some others have been reported in patents [49-51]. 
Aryl-alkylamine (such as fendiline), amino acids like phenyla-
lanine, leucine and isoleucine as well as dipeptides have also been  
Fig. (2). Structure of the two PAMs identified for the GABAB receptor.
shown to enhance GABAB receptor activity in brain slices [14, 37, 
38]. However, others reported that fendiline inhibits, rather than 
mimick, the effect of CGP7930 [58], and Urwyller and colleagues 
show that the effect of Aryl-alkylamine and amino acids are rather 
indirect, and do not result from a direct PAM action on the receptor 
itself [74]. 
  CGP7930 and GS39783 were found to enhance agonist potency 
as well as efficacy on recombinant GABAB receptors in various 
assays (Fig. 3), on both human and rat receptors [20, 76, 77]. 
GS39783 was also shown to be active on fish and chicken recep-
tors, but not on the Drosophila one [20], and CGP7930 enhances 
GABA affinity on the bullfrog receptor [1], demonstrating a good 
conservation of the allosteric site in vertebrates. In the GTPS bind-
ing assay CGP7930 and GS39783 increase GABA potency by 5-10 
fold, and increase the maximal effect from 1.5 to up to 2 fold, with 
potencies ranging from 3 to 5 M, depending on the agonist con-
centration. The same positive allosteric effect was also observed 
when coupling of the GABAB receptor to GIRK channels was 
measured in Xenopus oocytes [76, 77], or when the coupling of the 
receptor to phospholipase C was made possible with recombinant 
chimeric Gqi/o proteins [3, 76]. Very similar enhancing effects 
were observed with all three well known GABAB receptor agonists, 
GABA, baclofen and APPA. Of interest, the PAMs largely in-
creased the efficacy of partial agonists like CGP47656 to make it a 
full agonist, with a similar maximal effect as that of GABA. More-
over, among 7 competitive antagonists, two (CGP35348 and 2-OH-
saclofen) became partial agonists [75]. 
Fig. (3). The PAMs increase both the potency and efficacy of GABA on the 
GABAB receptor. Data were obtained from membranes prepared from HEK 
293 cells expressing GABAB1, GABAB2 and the Go proteins. GTPS bind-
ing was measured in the presence of the indicated concentration of GABA 
with (open triangles) or without (closed squares) 100 M CGP7930. This 
figure is adapted from [3].
  CGP7930 and GS39783 increased agonist affinity as measured 
with [
3H]-APPA or through the displacement of radio-labeled an-
tagonists [75-77]. However, the increase in affinity (2 fold) is lower 
than the measured increase in potency. In agreement with the allos-
teric potentiator further stabilizing the closed state of the GB1 VFT, 
a decrease in both the ON and OFF binding rates of agonists was 
observed, as well as a slight decrease in the affinity of most antago-
nists [63]. Only the affinities of the antagonists CGP35348 and 2-
OH-saclofen that became partial agonists in the presence of the 
PAMs, were increased [75]. 
  The two identified GABAB PAMs show no or only slight ago-
nist activity when applied alone in most assays, both in recombinant 
systems, and in native preparations [20, 59, 76, 77]. However, par-
tial agonist activity of CGP7930 could be observed when IP pro-
duction was measured in HEK293 cells co-expressing the GABAB
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consequence of endogenous agonists in the preparation since the 
competitive antagonists could not fully inhibit the effect of 
CGP7930. Although this likely results from the over-expression of 
the receptor and/or its coupling to non natural G-proteins, these data 
show that CGP7930 acts by stabilizing the receptor in its active 
state, an effect that is greatly favored in the presence of agonist. In 
agreement with this proposal, point mutations in the GABAB2
subunit were found to convert GS39783 from a pure PAM into a 
partial agonist, even though these mutations did not appear to gen-
erate a constitutively active receptor [20]. 
  To identify the mode of action of CGP7930, Binet and col-
leagues studied its effect on various combinations of wild-type and 
chimeric GABAB subunits, and took advantage of the agonist activ-
ity of this molecule in their assay [3]. This study revealed that the 
GABAB2 HD was required and sufficient for CGP7930 action. In-
deed, CGP7930 was found to activate GABAB2 subunit expressed 
alone, as well as a truncated version of this subunit corresponding 
to the HD only. Dupuis and colleagues make use of the absence of 
effect of GS39783 on the Drosophila GABAB receptor to identify 
its mechanism of action using chimeric drosophila/rat subunits [20]. 
They also bring further evidence for GS39783 acting in the HD of 
GABAB2. These authors also tried to identify the residues within the 
GABAB2 HD that interact with GS39783. Although no such resi-
dues were identified, mutations in TM6 were found to convert the 
modulator into an agonist, suggesting that the mutated residues are 
involved in stabilizing the GABAB2 HD into its inactive conforma-
tion. Residues of the extracellular side of TM7 were also found to 
decrease GS39783 efficacy, but not its potency, suggesting that 
these residues are involved in the allosteric coupling between the 
HD and the VFT in the GABAB receptor. It is quite surprising that 
among the large number of mutants generated, none affected 
GS39783 potency. More work is therefore needed to better under-
stand the mode of action of GABAB PAMs at the atomic level. 
  In summary, GABAB receptor activation is due to the closure of 
the GABAB1 VFT, that likely results in a relative movement of one 
subunit compare to the other. This new conformation of the het-
erodimer stabilizes the active conformation of the GABAB2 HD that 
promote the GDP-GTP exchange in the associated G-protein (Fig. 
4). As such there are two possibilities to enhance receptor activity. 
By further stabilizing the close state of GABAB1 VFT, as likely 
does Ca
2+, or stabilizing the active conformation of GABAB2 HD as 
do CGP7930 and GS39783 (Fig. 4). In the absence of agonist, these 
later compounds may still bind in the GABAB2 HD, but may not 
lead to the relative movement between the subunits, preventing 
them from being agonists (Fig. 4).
Fig. (4). Schematic view of the mechanism of action of GABAB PAMs as 
based on the proposed activation mechanism of this heterodimeric receptor. 
By stabilizing the closed state of the GABAB1 VFT (dark grey), Ca
2+ in-
creases GABA affinity and potency. By stabilizing the active conformation 
of the GABAB2 HD, small molecule PAMs increase both the potency and 
efficacy of agonists. The absence of agonist activity of these molecule may 
be due to their difficulty in promoting the relative movement between the 
subunits, a change that is proposed to play a critical role in receptor activa-
tion.
IN VIVO EFFECT OF POSITIVE ALLOSTERIC MODULA-
TORS (PAMS) 
Action of GABAB PAMs on Native Receptors 
  Soon after their identification and characterization on recombi-
nant GABAB receptors, the PAMs were shown to be effective on 
native receptors. This is nicely illustrated with the increase in ago-
nist affinity and the potentiation of baclofen stimulated GTPS
binding by both CGP7930 and GS39783 in rat cortical membranes 
[75-77], as well as in human fontal cortex membranes [58]. Meas-
urement of either the inhibition or stimulation of cAMP formation 
in native brain membranes and in vivo also confirmed the PAM 
activity of these two compounds at the native GABAB receptor [27, 
59]. When examined in brain slices, these compounds potentiated 
GABAB receptor action on synaptic transmission. GS39783 sup-
presses the paired pulse inhibition of population spikes recorded on 
hippocampal CA1 pyramidal cells, an effect that likely results from 
the potentiation of the action of ambiant GABA at pre-synaptic 
GABAB receptors located on GABAergic terminals [77]. The other 
GABAB enhancer CGP7930 enhances baclofen-induced depression 
of dopaminergic neurons in the ventral tegmental area [14] and the 
GABAergic synaptic transmission in the CA1 area of the hippo-
campus [13]. Surprisingly, no significant effect on excitatory syn-
aptic transmission in hippocampal CA1 network was observed [13] 
with CGP7930. It is proposed that this may result from a differen-
tial effect of this enhancer on the autoreceptors located in 
GABAergic terminals, and the heteroreceptors located in glutama-
tergic terminals. Although GABAB1a and GABAB1b splice variants 
have been shown to be differentially distributed in these two types 
of terminals [78], CGP7930 was found to be equally active on both 
recombinant receptors. Further studies are therefore required to 
clarify this issue. 
  Most importantly, both CGP7930 and GS39783 were found to 
pass the blood brain barrier when injected i.p. (or even when given 
orally in the case of GS39783) allowing the examination of their 
behavioral effects in vivo. Indeed, GS39783 decreased cAMP for-
mation in vivo in the striatum only when co-administered orally 
with a threshold concentration of baclofen [27]. In vivo efficacy of 
CGP7930 was also illustrated by its marked enhancement of the 
sedative and hypnotic effect of both baclofen and GHB in DBA 
mice [11]. Due to the original mechanism of action of these PAMs, 
it was therefore of interest to examine whether such compounds 
have different effects than the GABAB agonist baclofen. 
Differential Effects of PAMs and Agonists 
  Although baclofen is being used in the treatment of spasticity 
for multiple sclerosis patients, its myorelaxant, sedative, cognitive 
and hypothermic effects limit its use in a number of other patholo-
gies. In contrast to baclofen and other GABAB agonists that activate 
constantly and everywhere the receptor, PAMs are expected to 
enhance receptor activity only WHEN and WHERE needed physio-
logically (when and where GABA is produced to act on the GABAB
receptor) (Fig. 5). As such, differential effects of PAMs and ago-
nists were expected. Indeed, GS39783 given alone did not display 
sedative, cognitive, myorelaxant activities [18]. However, sedative 
effects were reported for CGP7930 at high doses [46]. No effect of 
GS39783 on body temperature was also observed [18]. This docu-
ment the general idea that PAMs could be a better alternative to 
baclofen for the treatment of pathologies in which such side effects 
are not desired. Of interest, as described in more details bellow, the 
PAMs display more pronounced anxiolytic effects than GABAB
agonists and keep most of the known positive actions of baclofen 
(Table 1). 
GABAB PAMs as Potential New Anxiolytics 
  The GABA system is well known to be involved in anxiety, as 
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ment of the GABAB receptor remained elusive for a long time due 
to the difficulty in assessing the effect of baclofen because of its 
above mentioned side effects. Anxiolytic effects of baclofen were 
however observed in some specific tests in rats, and also in humans 
[5, 17]. The generation of knockout mice deleted of either the 
GABAB1 or the GABAB2 gene confirmed a role of GABAB receptor 
in anxiety [17], as illustrated in several tests such as the light-dark 
box, the elevated plus maze or the elevated zero maze [18, 55]. In 
these same tests, the GABAB PAM GS39783 show strong anx-
iolytic activity, in contrast to baclofen [18, 55]. GS39783 was also 
efficient in reducing stress-induced hyperthermia [18], a test that 
could not be performed with baclofen due to its hypothermic action. 
Of most interest, the anxiolytic effect of GS39783 could still be 
observed after three weeks of treatment, demonstrating an absence 
of tolerence [55]. Moreover, no synergy with alcohol was observed 
[17]. As such, GABAB PAMs appear as a new class of anxiolytics 
that lack the side effects of the commonly used benzodiazepines. 
GABAB PAMs for the Treatment of Drug Addiction 
 The  GABAB receptor is known for its role in modulating the 
reinforcing effect of abused drugs such as cocaine, heroin, alcohol, 
amphetamine and nicotine [15]. In rats, baclofen decreases self-
administration of such drugs, and preclinical studies further indi-
cated the potential of baclofen for the treatment of cocaine, alcohol 
and nicotine dependence. In support of these effects, baclofen at-
tenuates the activation of limbic regions resulting from cocaine-
associated cues as revealed by neuroimaging in humans [7]. How-
ever, the use of baclofen as a therapeutic strategy for these indica-
tions is limited due to its side effects. The effect of GABAB PAMs 
on drug dependence and reinforcement has therefore been studied 
recently as a potential alternative to baclofen. 
  Both CGP7930 and GS39783 were found to inhibit cocaine 
self-administration in rats responding to different schedule of rein-
forcement [71]. Moreover, GS39783 inhibits the reward-facilitating 
effect of acute cocaine administration, as assessed by the reward 
threshold in intracranial self-stimulation paradigm [70]. The posi-
tive action of GS39783 on cocaine addiction is further supported by 
the inhibition of most biochemical and behavioral effects of acute 
and chronic cocaine treatment [45]. These include increased loco-
motor activity, up regulation of cAMP-response-element-binding 
protein (CREB) and phosphorylation of dopamine- and cAMP-
regulated phosphoprotein of 32 kDa (DARP32) in the nucleus ac-
cumbens and dorsal striatum [45]. 
 The  GABAB PAMs were also shown to have beneficial effects 
in alcohol consumption in rats. Like baclofen, CGP7930 or 
GS39783 reduced ethanol drinking behavior in two types of inbred 
alcohol-preferring rats [46, 60]. Both acquisition and maintenance 
of alcohol dependence were largely inhibited by PAMs, similarly to 
baclofen. 
  These first data reveal that GABAB PAMs represent a novel 
therapeutic strategy for the treatment of drug addiction, a strategy 
that will certainly benefit from the anxiolytic activity of these 
molecules.  
CONCLUSION 
  Although drugs activating the GABAB receptor were found to 
have a number of possible therapeutic actions, these were limited 
because of tolerance and undesired side effects which include seda-
tion, myorelaxing activity and hypothermia. By only enhancing the 
activity of GABAB receptors when and where needed, the GABAB
PAMs respect the physiological activity of the receptor (Fig. 5). 
Not surprisingly, PAMs were found to have different behavioral 
effects than the pure agonist baclofen. These molecules lack the 
undesired side effects of baclofen, can be used in long-term treat-
ment without tolerance, display a more pronounced anxiolytic ac-
tivity, and show similar positive effects as baclofen in drug addic-
tion. These observations make these modulators excellent alterna-
tives to baclofen for a number of therapeutic applications.  
  These recent findings on the GABAB receptor nicely illustrate 
the power of allosteric enhancers compared to agonists. After the 
Table 1.  Comparison of the Effect and Properties of GABAB Agonists and PAMs 
 Agonists  PAMs  Ref. 
tolerance  yes  Not after 3 weeks  [44, 55] 
Body temperature  decrease  No effect  [18] 
sedation  increase  No effect  [18] but see [46] 
myorelaxation  yes  No effect  [9, 18] 
cognition decrease No  effect  [18] 
Anxiety  variable  decrease  [5, 17, 18, 55] 
Cocaine self-admin  decrease  decrease  [15, 45, 70, 71] 
Alcohol intake  decrease  decrease  [15, 46, 60] 
Fig. (5). Major difference in the effect of agonists and PAMs acting at the 
GABAB receptor. Scheme illustrate biological responses resulting from the 
physiological activity of the GABAB receptor. In plain thick line is the re-
sponse mediated under control condition. In the presence of a pure agonist, 
the receptor is always activated, with a decline resulting from the desensiti-
zation of the system and tolerance to the drug (dashed thick line). In contrast 
the PAM does not activate the system unless GABA is released close to the 
receptor. As such, the PAM enhances the response mediated by physiologi-
cally released GABA, enhancing the GABA mediated response, WHEN and 
WHERE needed (dashed thin line).200    Current Neuropharmacology, 2007, Vol. 5, No. 3 Pin and Prézeau 
benzodiazepines acting as PAMs at the GABAA receptors, these 
data represent certainly the second best example of such a class of 
compounds. A search for similar molecules acting at other receptors 
is now open. 
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